Patients affected by severe genetic and rare diseases Patients affected by severe genetic and rare diseases Patients affected by severe genetic and rare diseases

Transforming the
Lives of Patients

WITH SEVERE GENETIC AND RARE DISEASES

We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and rare diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform READ MORE >>

spotlight

February 25, 2015

bluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress

Read More

February 24, 2015

bluebird bio Announces Participation in Upcoming Investor Conferences

Read More

February 2, 2015

FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major

Read More

January 29, 2015

bluebird bio Announces Transition of Chief Scientific Officer

Read More